Physician profile

Peter F Lawrence

Vascular Surgery · Los Angeles, CA

NPI 1730190323

$857.42

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

See the full distribution for Vascular Surgery

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$227.46

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
W. L. Gore & Associates, INC. $324.92 2019-2024 Gore Viabahn Vbx Balloon Expandable Endo
Abbott Laboratories $203.67 2019-2023 Perclose Proglide
Cook Medical LLC $116.99 2019
Bard Peripheral Vascular, INC. $114.63 2019
Medtronic, INC. $59.64 2021-2023 Endurant Iis
Integra Lifesciences Corporation $22.85 2022
Tactile Systems Technology INC $14.72 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Peter F Lawrence

$857.42

in general payments reported 2019-2025

Years
2019-2024
Top company
W. L. Gore & Associates, INC.

https://glasscript.com/doctor/896378/peter-f-lawrence

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.